Emerging threats in antifungal-resistant fungal pathogens

Frontiers in Medicine

Volumn 3, Issue MAR, 2016, Pages

  Sanglard, Dominique ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antifungals; Aspergillus; Candida; Drug resistance

Indexed keywords

EID: 85028063850     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2016.00011     Document Type: Review

References (101)

1. Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med (2012) 4:165rv13. doi: 10.1126/scitranslmed.3004404
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis (2004) 39:309-17. doi:10.1086/421946
3. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the transplant-associated infection surveillance network (TRANSNET) database. Clin Infect Dis (2010) 50:1091-100. doi:10.1086/651263
4. Denning DW, Bromley MJ. Infectious disease. How to bolster the antifungal pipeline. Science (2015) 347:1414-6. doi:10.1126/science.aaa6097
5. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis (2002) 2:73-85. doi:10.1016/s1473-3099(02)00181-0
6. Jessup CJ, Ghannoum MA, Ryder NS. An evaluation of the in vitro activity of terbinafine. Med Mycol (2000) 38:155-9. doi:10.1080/mmy.38.2.155.159
7. Anderson TM, Clay MC, Cioffi AG, Diaz KA, Hisao GS, Tuttle MD, et al. Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat Chem Biol (2014) 10:400-6. doi:10.1038/nchembio.1496
8. Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, Kanyemba C, et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis (2010) 50:338-44. doi:10.1086/649861
9. Arendrup MC. Update on antifungal resistance in Aspergillus and Candida. Clin Microbiol Infect (2014) 20(Suppl 6):42-8. doi:10.1111/1469-0691.12513
10. Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. using clinical and laboratory standards institute broth microdilution methods, 2010-2012. J Clin Microbiol (2012) 50:2846-56. doi:10.1128/JCM.00937-12
11. Pfaller MA, Castanheira M, Messer SA, Rhomberg PR, Jones RN. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp. Diagn Microbiol Infect Dis (2014) 79:198-204. doi:10.1016/j.diagmicrobio.2014.03.004
12. Delarze E, Sanglard D. Defining the frontiers between antifungal resistance, tolerance and the concept of persistence. Drug Resist Updat (2015) 23:12-9. doi:10.1016/j.drup.2015.10.001
13. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW. Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Updat (2013) 16:81-95. doi:10.1016/j.drup.2014.01.001
14. van Hal SJ, Chen SC-A, Sorrell TC, Ellis DH, Slavin M, Marriott DM. Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study. J Antimicrob Chemother (2014) 69:2210-4. doi:10.1093/jac/dku124
15. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW; The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole. Mycoses (2014) 57:377-9. doi:10.1111/myc.12170
16. Maubon D, Garnaud C, Calandra T, Sanglard D, Cornet M. Resistance of Candida spp. to antifungal drugs in the ICU: where are we now? Intensive Care Med (2014) 40:1-15. doi:10.1007/s00134-014-3404-7
17. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Moet GJ, Jones RN. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J Clin Microbiol (2010) 48:1592-9. doi:10.1128/JCM.02445-09
18. EUCAST-AFST. EUCAST technical note on fluconazole. Clin Microbiol Infect (2008) 14:193-5. doi:10.1111/j.1469-0691.2007.01899.x
19. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med (2012) 125:S3-13. doi:10.1016/j.amjmed.2011.11.001
20. Maligie MA, Selitrennikoff CP. Cryptococcus neoformans resistance to echinocandins: (1,3)β-glucan synthase activity is sensitive to echinocandins. Antimicrob Agents Chemother (2005) 49:2851-6. doi:10.1128/AAC.49.7.2851-2856.2005
21. Feldmesser M, Kress Y, Mednick A, Casadevall A. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis (2000) 182:1791-5. doi:10.1086/317614
22. Perlin DS, Shor E, Zhao Y. Update on antifungal drug resistance. Curr Clin Micro Rpt (2015) 2:84-95. doi:10.1007/s40588-015-0015-1
23. Fothergill AW, Sutton DA, McCarthy DI, Wiederhold NP. Impact of new antifungal breakpoints on antifungal resistance in Candida species. J Clin Microbiol (2014) 52:994-7. doi:10.1128/JCM.03044-13
24. Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis (2012) 55:1352-61. doi:10.1093/cid/cis697
25. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J Clin Microbiol (2003) 41:2176-9. doi:10.1128/JCM.41.5.2176-2179.2003
26. Pfaller MA, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Kroeger J, et al. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J Clin Microbiol (2009) 47:3185-90. doi:10.1128/JCM.00946-09
27. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis (2013) 56:1724-32. doi:10.1093/cid/cit136
28. Arendrup MC, Perlin DS. Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis (2014) 27:484-92. doi:10.1097/QCO.0000000000000111
29. Vermeulen E, Lagrou K, Verweij PE. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis (2013) 26:493-500. doi:10.1097/QCO.0000000000000005
30. Aller AI, Martin-Mazuelos E, Lozano F, Gomez-Mateos J, Steele-Moore L, Holloway WJ, et al. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother (2000) 44:1544-8. doi:10.1128/AAC.44.6.1544-1548.2000
31. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. Diagn Microbiol Infect Dis (2011) 71:252-9. doi:10.1016/j.diagmicrobio.2011.07.007
32. Gaur M, Puri N, Manoharlal R, Rai V, Mukhopadhayay G, Choudhury D, et al. MFS transportome of the human pathogenic yeast Candida albicans. BMC Genomics (2008) 9:579. doi:10.1186/1471-2164-9-579
33. Paulsen IT, Sliwinski MK, Nelissen B, Goffeau A, Saier MH. Unified inventory of established and putative transporters encoded within the complete genome of Saccharomyces cerevisiae. FEBS Lett (1998) 430:116-25. doi:10.1016/S0014-5793(98)00629-2
34. Prasad R, Goffeau A. Yeast ATP-binding cassette transporters conferring multidrug resistance. Annu Rev Microbiol (2012) 66:39-63. doi:10.1146/annurev-micro-092611-150111
35. Gbelska Y, Krijger J-J, Breunig KD. Evolution of gene families: the multidrug resistance transporter genes in five related yeast species. FEMS Yeast Res (2006) 6:345-55. doi:10.1111/j.1567-1364.2006.00058.x
36. Kovalchuk A, Driessen AJM. Phylogenetic analysis of fungal ABC transporters. BMC Genomics (2010) 11:177. doi:10.1186/1471-2164-11-177
37. Lamping E, Baret PV, Holmes AR, Monk BC, Goffeau A, Cannon RD. ScienceDirect-fungal genetics and biology: fungal PDR transporters: phylogeny, topology, motifs and function. Fungal Genet Biol (2010) 47:127-42. doi:10.1016/j.fgb.2009.10.007
38. Costa C, Dias PJ, Sá-Correia I, Teixeira MC. MFS multidrug transporters in pathogenic fungi: do they have real clinical impact? Front Physiol (2014) 5:197-197. doi:10.3389/fphys.2014.00197
39. Sanglard D, Coste A, Ferrari S. Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res (2009) 9:1029-50. doi:10.1111/j.1567-1364.2009.00578.x
40. Coleman JJ, Mylonakis E. Efflux in fungi: la pièce de résistance. PLoS Pathog (2009) 5:e1000486. doi:10.1371/journal.ppat.1000486.t002
41. Slaven JW, Anderson MJ, Sanglard D, Dixon GK, Bille J, Roberts IS, et al. Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal Genet Biol (2002) 36:199-206. doi:10.1016/S1087-1845(02)00016-6
42. Nascimento AM, Goldman GH, Park S, Marras SAE, Delmas G, Oza U, et al. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob Agents Chemother (2003) 47:1719-26. doi:10.1128/aac.47.5.1719-1726.2003
43. da Silva Ferreira ME, Malavazi I, Savoldi M, Brakhage AA, Goldman MH, Kim HS, et al. Transcriptome analysis of Aspergillus fumigatus exposed to voriconazole. Curr Genet (2006) 50:32-44. doi:10.1007/s00294-006-0073-2
44. Fraczek MG, Bromley M, Buied A, Moore CB, Rajendran R, Rautemaa R, et al. The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother (2013) 68:1486-96. doi:10.1093/jac/dkt075
45. Lamping E, Monk BC, Niimi K, Holmes AR, Tsao S, Tanabe K, et al. Characterization of three classes of membrane proteins involved in fungal azole resistance by functional hyperexpression in Saccharomyces cerevisiae. Eukaryot Cell (2007) 6:1150-65. doi:10.1128/EC.00091-07
46. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother (1995) 39:2378-86. doi:10.1128/aac.39.11.2378
47. Calabrese D, Bille J, Sanglard, D. A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole. Microbiology (2000) 146(Pt 11):2743-54. doi:10.1099/00221287-146-11-2743
48. Coste AT, Karababa M, Ischer F, Bille J, Sanglard D. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell (2004) 3:1639-52. doi:10.1128/EC.3.6.1639-1652.2004
49. Morschhäuser J, Barker KS, Liu TT, BlaB-Warmuth J, Homayouni R, Rogers PD. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog (2007) 3:e164. doi:10.1371/journal.ppat.0030164
50. Coste A, Turner V, Ischer F, Morschhäuser J, Forche A, Selmecki A, et al. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics (2006) 172:2139-56. doi:10.1534/genetics.105.054767
51. Dunkel N, Blass J, Rogers PD, Morschhäuser J. Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol Microbiol (2008) 69:827-40. doi:10.1111/j.1365-2958.2008.06309.x
52. Ferrari S, Ischer F, Calabrese D, Posteraro B, Sanguinetti M, Fadda G, et al. Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog (2009) 5:e1000268. doi:10.1371/journal.ppat.1000268
53. Vermitsky J-P, Earhart KD, Smith WL, Homayouni R, Edlind TD, Rogers PD. Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies. Mol Microbiol (2006) 61:704-22. doi:10.1111/j.1365-2958.2006.05235.x
54. Dunkel N, Liu TT, Barker KS, Homayouni R, Morschhäuser J, Rogers PD. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. Eukaryot Cell (2008) 7:1180-90. doi:10.1128/EC.00103-08
55. Snelders E, Melchers WJG, Verweij PE. Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis? Future Microbiol (2011) 6:335-47. doi:10.2217/fmb.11.4
56. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. Candida biofilms: an update. Eukaryot Cell (2005) 4:633-8. doi:10.1128/EC.4.4.633-638.2005
57. Mitchell KF, Zarnowski R, Sanchez H, Edward JA, Reinicke EL, Nett JE, et al. Community participation in biofilm matrix assembly and function. Proc Natl Acad Sci U S A (2015) 112(13):4092-7. doi:10.1073/pnas.1421437112
58. Desai JV, Mitchell AP, Andes DR. Fungal biofilms, drug resistance, and recurrent infection. Cold Spring Harb Perspect Med (2014) 4:a019729-019729. doi:10.1101/cshperspect.a019729
59. Bonhomme J, d'Enfert C. Candida albicans biofilms: building a heterogeneous, drug-tolerant environment. Curr Opin Microbiol (2013) 16:398-403. doi:10.1016/j.mib.2013.03.007
60. Vediyappan G, Rossignol T, d'Enfert C. Interaction of Candida albicans biofilms with antifungals: transcriptional response and binding of antifungals to beta-glucans. Antimicrob Agents Chemother (2010) 54:2096-111. doi:10.1128/AAC.01638-09
61. Maebashi K, Kudoh M, Nishiyama Y, Makimura K, Uchida K, Mori T, et al. A novel mechanism of fluconazole resistance associated with fluconazole sequestration in Candida albicans isolates from a myelofibrosis patient. Microbiol Immunol (2002) 46:317-26. doi:10.1111/j.1348-0421.2002.tb02702.x
62. Hope WW, Tabernero L, Denning DW, Anderson MJ. Molecular mechanisms of primary resistance to flucytosine in Candida albicans. Antimicrob Agents Chemother (2004) 48:4377-86. doi:10.1128/AAC.48.11.4377-4386.2004
63. Edlind TD, Katiyar SK. Mutational analysis of flucytosine resistance in Candida glabrata. Antimicrob Agents Chemother (2010) 54:4733-8. doi:10.1128/AAC.00605-10
64. Vandeputte P, Pineau L, Larcher G, Noël T, Brèthes D, Chabasse D, et al. Molecular mechanisms of resistance to 5-fluorocytosine in laboratory mutants of Candida glabrata. Mycopathologia (2011) 171:11-21. doi:10.1007/s11046-010-9342-1
65. Lamb D, Kelly D, White T, Kelly S. The R467K amino acid substitution in Candida albicans sterol 14alpha-demethylase causes drug resistance through reduced affinity. Antimicrob Agents Chemother (2000) 44:63-7. doi:10.1128/aac.44.1.63-67.2000
66. Sanglard D, Coste AT. Activity of isavuconazole and other azoles against Candida clinical isolates and yeast model systems with known azole resistance mechanisms. Antimicrob Agents Chemother (2015) 60:229-38. doi:10.1128/AAC.02157-15
67. Morio F, Loge C, Besse B, Hennequin C, Le Pape P. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis (2010) 66:373-84. doi:10.1016/j.diagmicrobio.2009.11.006
68. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother (2003) 47:1120-4. doi:10.1128/AAC.47.3.1120-1124.2003
69. Garcia-Effron G, Mellado E, Gomez-Lopez A, Alcazar-Fuoli L, Cuenca-Estrella M, Rodríguez-Tudela JL. Differences in interactions between azole drugs related to modifications in the 14-alpha sterol demethylase gene (cyp51A) of Aspergillus fumigatus. Antimicrob Agents Chemother (2005) 49:2119-21. doi:10.1128/AAC.49.5.2119-2121.2005
70. Perlin DS. Echinocandin resistance in Candida. Clin Infect Dis (2015) 61:S612-7. doi:10.1093/cid/civ791
71. Asner SA, Giulieri S, Diezi M, Marchetti O, Sanglard D. Acquired multidrug antifungal resistance in Candida lusitaniae during therapy. Antimicrob Agents Chemother (2015) 59. doi:10.1128/AAC.02204-15
72. Desnos-Ollivier M, Moquet O, Chouaki T, Guerin AM, Dromer F. Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment. J Clin Microbiol (2011) 49:2304-6. doi:10.1128/JCM.00325-11
73. Desnos-Ollivier M, Bretagne S, Raoux D, Hoinard D, Dromer F, Dannaoui E, et al. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob Agents Chemother (2008) 52:3092-8. doi:10.1128/AAC.00088-08
74. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother (2008) 52:2305-12. doi:10.1128/AAC.00262-08
75. Kelly S, Lamb D, Corran A, Baldwin B, Kelly D. Mode of action and resistance to azole antifungals associated with the formation of 14alpha-methylergosta-8,24(28)-dien-3β,6a-diol. Biochem Biophys Res Commun (1995) 207:910-5. doi:10.1006/bbrc.1995.1272
76. Chau AS, Gurnani M, Hawkinson R, Laverdiere M, Cacciapuoti A, McNicholas PM. Inactivation of sterol delta5,6-desaturase attenuates virulence in Candida albicans. Antimicrob Agents Chemother (2005) 49:3646-51. doi:10.1128/AAC.49.9.3646-3651.2005
77. Eddouzi J, Parker JE, Vale-Silva LA, Coste A, Ischer F, Kelly S, et al. Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals. Antimicrob Agents Chemother (2013) 57:3182-93. doi:10.1128/AAC.00555-13
78. Martel CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AGS, et al. Identification and characterization of four azole-resistant erg3 mutants of Candida albicans. Antimicrob Agents Chemother (2010) 54:4527-33. doi:10.1128/AAC.00348-10
79. Morio F, Pagniez F, Lacroix C, Miegeville M, Le Pape P. Amino acid substitutions in the Candida albicans sterol Δ5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence. J Antimicrob Chemother (2012) 67:2131-8. doi:10.1093/jac/dks186
80. Jensen-Pergakes KL, Kennedy MA, Lees ND, Barbuch R, Koegel C, Bard M. Sequencing, disruption, and characterization of the Candida albicans sterol methyltransferase (ERG6) gene: drug susceptibility studies in erg6 mutants. Antimicrob Agents Chemother (1998) 42:1160-7
81. Jia N, Arthington-Skaggs B, Lee W, Pierson CA, Lees ND, Eckstein J, et al. Candida albicans sterol C-14 reductase, encoded by the ERG24 gene, as a potential antifungal target site. Antimicrob Agents Chemother (2002) 46:947-57. doi:10.1128/AAC.46.4.947-957.2002
82. Vincent BM, Lancaster AK, Scherz-Shouval R, Whitesell L, Lindquist S. Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol (2013) 11:e1001692. doi:10.1371/journal.pbio.1001692
83. Dodgson AR, Dodgson KJ, Pujol C, Pfaller MA, Soll DR. Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob Agents Chemother (2004) 48:2223-7. doi:10.1128/AAC.48.6.2223-2227.2004
84. Verweij PE, Kema GHJ, Zwaan B, Melchers WJG. Triazole fungicides and the selection of resistance to medical triazoles in the opportunistic mould Aspergillus fumigatus. Pest Manag Sci (2013) 69:165-70. doi:10.1002/ps.3390
85. Snelders E, van der Lee HAL, Kuijpers J, Rijs AJMM, Varga J, Samson RA, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med (2008) 5:e219. doi:10.1371/journal.pmed.0050219
86. van der Linden JWM, Camps SMT, Kampinga GA, Arends JPA, Debets-Ossenkopp YJ, Haas PJA, et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis (2013) 57:513-20. doi:10.1093/cid/cit320
87. van der Linden JWM, Arendrup MC, Warris A, Lagrou K, Pelloux H, Hauser PM, et al. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis (2015) 21:1041-4. doi:10.3201/eid2106.140717
88. Wiederhold NP, Gil VG, Gutierrez F, Lindner JR, Albataineh MT, Mccarthy DI, et al. First Detection of TR34 L98H and TR46 Y121F T289A Cyp51 Mutations Aspergillus fumigatus isolates in the United States. J Clin Microbiol (2016) 54:168-71. doi:10.1128/JCM.02478-15
89. Snelders E, Camps SMT, Karawajczyk A, Schaftenaar G, Kema GHJ, van der Lee HA, et al. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One (2012) 7:e31801. doi:10.1371/journal.pone.0031801
90. Bader O, Tünnermann J, Dudakova A, Tangwattanachuleeporn M, Weig M, Gross U. Environmental isolates of azole-resistant Aspergillus fumigatus in Germany. Antimicrob Agents Chemother (2015) 59:4356-9. doi:10.1128/AAC.00100-15
91. Perlin DS. Current perspectives on echinocandin class drugs. Future Microbiol (2011) 6:441-57. doi:10.2217/fmb.11.19
92. Martel CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AGS, et al. A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B. Antimicrob Agents Chemother (2010) 54:3578-83. doi:10.1128/AAC.00303-10
93. Sanglard D, Ischer F, Parkinson T, Falconer D, Bille J. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother (2003) 47:2404-12. doi:10.1128/aac.47.8.2404-2412.2003
94. Vale-Silva LA, Coste AT, Ischer F, Parker JE, Kelly SL, Pinto E, et al. Azole resistance by loss of function of the sterol d5,6-desaturase gene (ERG3) in Candida albicans does not necessarily decrease virulence. Antimicrob Agents Chemother (2012) 56:1960-8. doi:10.1128/AAC.05720-11
95. Pinjon E, Moran GP, Jackson CJ, Kelly SL, Sanglard D, Coleman DC, et al. Molecular mechanisms of itraconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother (2003) 47:2424-37. doi:10.1128/aac.47.8.2424-2437.2003
96. Park S, Kelly R, Kahn JN, Robles J, Hsu M-J, Register E, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother (2005) 49:3264-73. doi:10.1128/AAC.49.8.3264-3273.2005
97. Chapeland-Leclerc F, Hennequin C, Papon N, Noël T, Girard A, Socié G, et al. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob Agents Chemother (2010) 54:1360-2. doi:10.1128/AAC.01138-09
98. Pham CD, Iqbal N, Bolden CB, Kuykendall RJ, Harrison LH, Farley MM, et al. Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother (2014) 58:4690-6. doi:10.1128/AAC.03255-14
99. Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis (2014) 20:1833-40. doi:10.3201/eid2011.140685
100. Jensen RH, Astvad KMT, Silva LV, Sanglard D, Jorgensen R, Nielsen KF, et al. Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations. J Antimicrob Chemother (2015) 70:1-5. doi:10.1093/jac/dkv140
101. Healey KR, Lockhart SR, Sobel JD, Farmakiotis D, Kontoyiannis DP, Sanglard D, et al. Candida glabrata mutator phenotype promotes resistance to multiple antifungal drugs. Mycoses (2015) 58:51-226. doi:10.1111/myc.12380